Pharmaceutical Product Development, LLC (PPD), a leading global contract research organization (CRO), was named the winner of the CRO Quality Award from the Association of Clinical Research Professionals (ACRP) and The Avoca Groupduring the recent ACRP annual...
hRPC Cell Therapy Demonstrates Sustained and Further Improvement in Vision at 60 and 120 Days in First Cohort of Phase 2a study in Retinitis Pigmentosa Mean Change from Baseline in Visual Acuity of +23 Letters to Date LONDON, April 26, 2019 /PRNewswire/...
The WINTHER trial***, NCT01856296, led by investigators from Vall d’Hebron Institute of Oncology – VHIO (Spain), Chaim Sheba Medical Center (Israel) (Raanan Berger), Gustave Roussy (France) (Jean-Charles Soria), Centre Léon Bérard (France) (Pierre...
Presentation to provide overview of Phase 2 T-CALM study design, results and clinical path forward Cavion, Inc., a leading clinical stage biotechnology company committed to developing novel therapeutics for people with neurological diseases, announced today that the...
At the Alliance for Regenerative Medicine’s Cell and Gene Therapy ‘Meeting on the Med’ in Barcelona Rexgenero, a regenerative medicine company pioneering the development of advanced cell-based therapies to treat critical limb ischaemia (CLI), today presented an update...
Data from a Prospectively Designed Independent Trial of 130 Patients showed that PyL upstaged and downstaged disease in 65.5% of patients Progenics Pharmaceuticals, Inc. (PGNX), an oncology company developing innovative targeted medicines and artificial intelligence...
Email
Text